LivaNova (NASDAQ:LIVN) Sets New 52-Week High – Here’s What Happened

LivaNova PLC (NASDAQ:LIVN) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $77.80 and last traded at $77.1650, with a volume of 30536 shares trading hands. The stock had previously closed at $74.80.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on LIVN shares. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Robert W. Baird dropped their price objective on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Piper Sandler reiterated an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a research note on Thursday, February 19th. Barclays increased their price objective on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Finally, Mizuho increased their price objective on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $79.38.

LivaNova Trading Up 1.6%

The company has a market capitalization of $4.31 billion, a price-to-earnings ratio of 40.19 and a beta of 0.88. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The company’s 50 day simple moving average is $68.46 and its two-hundred day simple moving average is $65.50.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.13. The business had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the company posted $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, research analysts anticipate that LivaNova PLC will post 3.72 earnings per share for the current fiscal year.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares in the company, valued at approximately $547,521. This represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Institutional investors and hedge funds have recently modified their holdings of the stock. Millennium Management LLC boosted its position in LivaNova by 17.3% during the fourth quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock worth $214,376,000 after acquiring an additional 514,268 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in shares of LivaNova by 94.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after acquiring an additional 1,179,436 shares during the period. Wellington Management Group LLP increased its stake in LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after buying an additional 1,067,349 shares during the period. Vanguard Group Inc. increased its stake in LivaNova by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after buying an additional 34,812 shares during the period. Finally, AQR Capital Management LLC increased its stake in LivaNova by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock worth $132,606,000 after buying an additional 496,165 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.